Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Christian P. Pilarsky

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7968-3283; OpenAlex author ID A5014489598. Sources: OpenAlex.

Their work

Papers
72 (first author 2, last author 15)
Trials
0
Grants
0
Labs led
2
Collaborators
260
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: 3 papers · 2014: 8 papers · 2015: 4 papers · 2016: 2 papers · 2017: 3 papers · 2018: 4 papers · 2019: 11 papers · 2020: 1 paper · 2021: 4 papers · 2022: 8 papers · 2023: 6 papers · 2024: 4 papers · 2025: 6 papers · 2026: 1 paper

Papers 50 of 72

  1. Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117035↗
  2. CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. Last author DOI 10.1016/j.semcancer.2025.07.004↗
  3. Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03051-z↗
  4. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  5. Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathw… Co-author DOI 10.1038/s41598-025-95766-5↗
  6. Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Last author DOI 10.3390/cancers17193181↗
  7. Identification of Cancer Associated Fibroblasts Related Genes Signature to Facilitate Improved Prediction of Prognosis and Responses to Therapy in Patients wit… Co-author DOI 10.3390/ijms26104876↗
  8. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Last author DOI 10.1038/s41420-024-01890-y↗
  9. MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-332350↗
  10. Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3419↗
  11. The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers. Co-author DOI 10.1186/s13046-024-03117-5↗
  12. A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. Co-author DOI 10.1038/s41420-023-01334-z↗
  13. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  14. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patient… Co-author DOI 10.1186/s13045-023-01404-w↗
  15. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2023.1157397↗
  16. Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. Last author DOI 10.3390/cancers15194842↗
  17. Mitoxantrone and Mitoxantrone-Loaded Iron Oxide Nanoparticles Induce Cell Death in Human Pancreatic Ductal Adenocarcinoma Cell Spheroids. Co-author DOI 10.3390/ma16072906↗
  18. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00703-8↗
  19. Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Co-author DOI 10.1038/s41586-022-05062-9↗
  20. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  21. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Last author DOI 10.1186/s13046-022-02443-w↗
  22. An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer. Co-author DOI 10.3389/fcell.2022.975684↗
  23. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Last author DOI 10.3390/cancers14020326↗
  24. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.3390/cancers14133152↗
  25. Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. Last author DOI 10.3390/cancers15010241↗
  26. Pre-clinical Models of Metastasis in Pancreatic Cancer. Last author DOI 10.3389/fcell.2021.748631↗
  27. Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants. Co-author DOI 10.3390/cancers13112654↗
  28. Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers13153820↗
  29. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  30. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  31. Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imagin… Co-author DOI 10.1002/prca.201800046↗
  32. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Co-author DOI 10.1016/j.ebiom.2019.01.037↗
  33. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Co-author DOI 10.1126/science.aaw3145↗
  34. β8 Integrin Mediates Pancreatic Cancer Cell Radiochemoresistance. Co-author DOI 10.1158/1541-7786.mcr-18-1352↗
  35. CRISPR Cas9 in Pancreatic Cancer Research. Last author DOI 10.3389/fcell.2019.00239↗
  36. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer. Last author DOI 10.3390/ijms20133305↗
  37. The Role of Exosomes in Pancreatic Cancer. Last author DOI 10.3390/ijms20184332↗
  38. Chemoresistance in Pancreatic Cancer. Co-author DOI 10.3390/ijms20184504↗
  39. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Co-author DOI 10.3390/ijms20184543↗
  40. Silenced ZNF154 Is Associated with Longer Survival in Resectable Pancreatic Cancer. Co-author DOI 10.3390/ijms20215437↗
  41. CRISPR/Cas9-Mediated Knock-Out of Kras G12D Mutated Pancreatic Cancer Cell Lines. Co-author DOI 10.3390/ijms20225706↗
  42. Analysis of DNA Hypermethylation in Pancreatic Cancer Using Methylation-Specific PCR and Bisulfite Sequencing. First author DOI 10.1007/978-1-4939-8751-1_16↗
  43. Identification of Prognostic Biomarkers by Combined mRNA and miRNA Expression Microarray Analysis in Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2018.03.003↗
  44. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1136/gutjnl-2016-312432↗
  45. The Effect of GPRC5a on the Proliferation, Migration Ability, Chemotherapy Resistance, and Phosphorylation of GSK-3β in Pancreatic Cancer. Co-author DOI 10.3390/ijms19071870↗
  46. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Co-author DOI 10.1038/ncb3513↗
  47. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  48. The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation. Co-author DOI 10.1371/journal.pone.0170390↗
  49. In silico analysis of the transportome in human pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00249-016-1171-9↗
  50. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗

Closest collaborators

The 25 strongest of 260 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert Grützmann · 40 shared papers, 2011–2026 · strength 4.33
  2. Hai Yang · 11 shared papers, 2017–2024 · strength 1.46
  3. Nathalie Britzen‐Laurent · 8 shared papers, 2022–2025 · strength 1.28
  4. Bin Lan · 7 shared papers, 2019–2025 · strength 1.11
  5. Andrew Victor Biankin · 9 shared papers, 2012–2025 · strength 1.06
  6. David Kuang-Fu Chang · 7 shared papers, 2012–2025 · strength 0.88
  7. Yanxi Lu · 4 shared papers, 2024–2025 · strength 0.84
  8. Peter J. Bailey · 5 shared papers, 2019–2025 · strength 0.64
  9. Debabrata Mukhopadhyay · 4 shared papers, 2021–2025 · strength 0.61
  10. Thomas Knösel · 8 shared papers, 2012–2024 · strength 0.59
  11. Bin Liu · 5 shared papers, 2017–2022 · strength 0.59
  12. Georg F. Weber · 4 shared papers, 2018–2025 · strength 0.58
  13. David Arthur Tuveson · 5 shared papers, 2012–2025 · strength 0.51
  14. Daniel Schreyer · 3 shared papers, 2022–2025 · strength 0.51
  15. Nils Cordes · 3 shared papers, 2019–2025 · strength 0.49
  16. Shuman Zhang · 3 shared papers, 2021–2024 · strength 0.49
  17. Christoph Kahlert · 5 shared papers, 2014–2023 · strength 0.48
  18. Marius Distler · 5 shared papers, 2014–2023 · strength 0.46
  19. Siyuan Zeng · 3 shared papers, 2019–2022 · strength 0.38
  20. Jinping Zhang · 2 shared papers, 2023–2024 · strength 0.33
  21. Duo Yun · 2 shared papers, 2022–2024 · strength 0.31
  22. Frank Ulrich Weiß · 4 shared papers, 2014–2022 · strength 0.31
  23. Julia V. Mayerle · 4 shared papers, 2014–2022 · strength 0.31
  24. Stephan B. Dreyer · 2 shared papers, 2020–2025 · strength 0.30
  25. Hang He · 2 shared papers, 2022–2024 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.